1. France Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Boiron S.A.

Boiron S.A.

BOIRF
Boiron S.A.US flagOther OTC
31.50
USD
- -
- -
546.91MMarket Cap
Boiron S.A.
BOIRF
(Other OTC)

Recent

price

31.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
24.25
24.38
26.61
31.81
31.64
32.95
33.34
33.51
33.96
31.81
29.33
25.99
30.72
28.41
28.08
28.86
Revenue per Share
2.02
1.97
2.36
4.24
4.62
4.01
4.22
4.25
3.23
2.32
1.5
1.63
2.57
2.06
0.65
1.88
Basic EPS, GAAP
0.45
0.26
3.19
4.25
3.79
4.18
4.09
2.79
2.06
0.76
2.72
0.74
2.31
1.58
1.36
1.71
Free Cash Flow per Basic Share
0.7
0.7
0.71
0.9
1.21
1.5
1.5
1.6
1.59
1.45
1.05
0.95
0.95
11.46
1.35
1.2
Dividend per Share
12.29
13.45
11.57
16.06
15.56
18.22
21.14
23.74
22.83
24.3
24.52
25.8
27.47
1.01
1.01
1.01
Book Value per Share
10.34
11.13
9.4
13.73
13.28
15.87
19.01
21.64
20.8
22.2
22.25
23.47
24.81
15.65
14.93
15.72
Tangible Book Value per Share
21
21
21
19
19
18
18
18
18
18
18
18
17
17
17
17
Basic Weighted Avg Shares
521
523
566
618
610
608
614
618
604
557
514
455
534
493
488
501
Sales/Revenue/Turnover
12.8
12.88
15.33
21.92
23.46
21.42
21.07
19.78
16.41
13.2
13.58
8.69
10.6
8.27
7.35
7.26
Operating Margin (%)
35
19
33
33
18
29
29
29
34
38
69
18
17
26
42
19
Depreciation Expense
43
42
50
82
89
74
78
78
57
41
26
29
45
36
11
33
Net Income, GAAP
35.31
37.35
39.68
37.24
36.98
40.13
38.76
36.49
44.75
36.97
29.58
38.07
25.2
27.56
22.24
23.84
Effective Tax Rate (%)
8.31
8.07
8.88
13.34
14.6
12.16
12.65
12.67
9.51
7.29
5.1
6.27
8.36
7.26
2.33
6.51
Profit Margin (%)
137
120
123
187
193
227
276
306
254
276
265
294
325
160
169
161
Working Capital
3
3
3
3
4
5
5
5
4
10
9
8
17
7
10
19
LT Debt
344
369
326
392
380
416
470
517
486
505
509
532
557
392
378
393
Total Equity
12.58
11.55
14.67
22.86
22.53
19.02
17.49
15.33
10.69
9.16
9.43
4.59
7.53
6
6.97
6.77
Return on Invested Capital (%)
33.99
15
18.57
29.09
28.64
22.81
21.08
18.47
13.3
9.62
6.01
6.35
9.44
14.59
39.86
82.07
Return on Capital (%)
17.42
15.3
18.81
29.53
29.12
23.25
21.42
18.92
13.62
9.77
6.13
6.48
9.61
14.47
64.61
186.05
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.17%
-4.01%
3.86%
Free Cash Flow
24.87%
23.67%
25.9%
Net Income, GAAP
7.97%
33.04%
187.96%
Sales/Revenue/Turnover
-1.62%
-0.01%
2.78%
Total Cash Common Dividend
96.08%
199.22%
-11.11%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
493
2024
- -
- -
- -
- -
488
2025
- -
- -
- -
- -
501

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.06
2024
- -
- -
- -
- -
0.65
2025
- -
- -
- -
- -
1.88

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
11.46
2024
- -
- -
- -
- -
1.35
2025
- -
- -
- -
- -
1.2
Similar Companies
Perrigo Company plc (PRGO)
Stem Holdings, Inc. (STEM.CN)
MedMen Enterprises Inc. (MMNFF)
Better Plant Sciences Inc. (PLNT.CN)
Joyzyme Group Limited (8622.HK)
Bausch Health Companies Inc. (BHC)
Business
Boiron S.A. Boiron SA researches, develops, manufactures, and distributes homeopathic medicines worldwide as the global leader in the sector. The company produces over 1,500 remedies including non-proprietary generic homeopathic medicines and proprietary over-the-counter specialties such as Oscillococcinum for flu symptoms, Stodal and Stodaline cough syrups, Arnigel and Arnicalme topical gels for pain relief and bruising, Camilia for teething discomfort, Sedatif PC for sleep disorders, Coryzalia for cold symptoms, Homeoptic eye drops, and Homeovox for vocal issues; it also offers plant-based phytotherapy products, cosmetics like diaper creams with over 99% natural ingredients, nutritional supplements, and storage solutions sold through pharmacies, chains, wholesalers, grocery stores, health food outlets, and online platforms. Boiron operates through integrated facilities handling registration to distribution, with production plants and a new 18,000 square meter global distribution platform in Olmes equipped with advanced robotics; it maintains subsidiaries in more than 50 countries across Europe, North America including strong U.S. presence generating significant e-commerce revenue, South America, Africa, the Middle East, and other regions. Founded in 1932 by pharmacist brothers Jean and Henri Boiron in Paris, France, the company expanded via mergers in 1967, relocated headquarters and main production to Ste. Foy-lès-Lyon near Lyon in 1974, and now bases operations in Messimy, France. Recent developments include EW Healthcare Partners acquiring a 25% minority stake in Boiron Développement in September 2025 at an €875 million enterprise value with the Boiron family transferring their 70% stake to support growth into new healthcare verticals especially in the U.S., launching a renewable energy self-consumption project in Messimy in February 2025, receiving a Parents' Community Award for its diaper cream in April 2025, and participating in the Courir pour Elles solidarity run against women's cancers in July 2025; governance changes occurred in July 2024 alongside a new diversification strategy.